- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05184205
Photodynamic Therapy for COVID-19 Prevention
Photodynamic Therapy for SARS-CoV-2 Viral Reduction in the Upper Airway in PCR-positive Asymptomatic Individuals.
Study Overview
Status
Intervention / Treatment
Detailed Description
There is a wide variety of people who test positive for SARS-CoV-2. This is directly dependent upon their exposure to the virus, their age and any medical comorbidities that they may have. At this time, it is not possible to predict who will have an adequate immune response to avoid getting COVID-19. Since this remains unpredictable a universal approach to treating SARS-CoV-2 positive patients may be the optimal approach.
The rational for this study design is that in a real world setting numerous patients across a wide variety of conditions will receive testing for SARS-CoV-2 for a variety of reasons. For those who test positive and are asymptomatic or have only mild symptoms, the current standard of care is observation and quarantine. The incubation period can range from 2-14 days with a mean of 5-6 days. Depending upon an individual's original inoculum of virus, comorbidities and other factors they may progress to COVID-19. Preemptive treatment during this time frame may avoid or mitigate COVID-19 disease severity. In certain high-risk individuals attenuating the disease may avoid hospitalization or death, ICU admission and shorten hospital stays.
The nasal disinfection process rapidly and lethally disrupts the microbial cell wall, leaving human tissue unharmed. The topically applied photosensitizer formulation selectively stains bacteria by binding with microbial cell wall components. The red light is absorbed by the photosensitizer molecules, causing electronic state transitions within the photosensitizer. The excited photosensitizer immediately transfers energy to surrounding molecular oxygen, thereby producing reactive oxygen species (ROS) that are responsible for the lethal cell wall disruption.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Pamplona, Spain, 31008
- Clinica Universidad de Navarra
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female ≥ 18 years of age
- Patient showing a positive test for SARS-CoV-2 with < 26 Ct of an FDA-approved PCR test who is symptomatic or flu-like illness or pneumonia
- Ability to tolerate an 12-minute non-painful nasal light illumination
Exclusion Criteria:
- Inability to tolerate insertion of the light illuminator due to oronasal size, shape, or anatomical variants
- Known allergic reactions to components of the nasal decolonization treatment including methylene blue or chlorhexidine gluconate.
- COVID-19 illness that is moderate or severe in nature.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active Intervention
The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares.
The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils.
The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation.
Illumination stops automatically upon completion of the 4-minute cycle.
The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
|
The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares.
The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils.
The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation.
Illumination stops automatically upon completion of the 4-minute cycle.
The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
|
Sham Comparator: Sham Comparator: Control
Sham comparator
|
Patients who are SARS-CoV-2 positive whose PCR levels are followed but no active intervention will be done.
Saline will be used in their nose and the light device will be inserted but not turned on.
Patient will be wearing light protecting glasses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SARS-CoV-2 viral titer reduction
Time Frame: Immediately following treatment and on days 3, 7, and 14.
|
Change from baseline PCR count with testing on days 3, 7 and 14
|
Immediately following treatment and on days 3, 7, and 14.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
General safety of nasal photodisinfection
Time Frame: 14 days post treatment
|
Observation for any adverse events
|
14 days post treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Josepmaria Argemi, MD, Clinica Universidad de Navarra
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SARS_PDT01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV-2 Acute Respiratory Disease
-
St. Olavs HospitalThe Research Council of Norway; Helse Nord-Trøndelag HF; Alesund Hospital; Namsos... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 Sepsis | SARS CoV 2 InfectionNorway
-
Chulalongkorn UniversityRamathibodi Hospital; Ministry of Health, Thailand; The Government Pharmaceutical... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS CoV 2 InfectionThailand
-
BioNTech SECompletedCOVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)United States, Germany, Turkey, South Africa
-
University of Iowa3MWithdrawnSARS-CoV-2 Acute Respiratory Disease
-
The Board of MedicineApollo Neuroscience, Inc.RecruitingPost-acute Sequelae of SARS-COV-2 InfectionUnited States
-
Everly HealthCompletedSARS-CoV-2 Acute Respiratory DiseaseUnited States
-
Qihan LiNot yet recruitingSARS-CoV-2 Acute Respiratory Disease
-
Everly HealthCompletedSARS-CoV-2 Acute Respiratory DiseaseUnited States
-
Imam Abdulrahman Bin Faisal UniversityDammam Medical Complex; Institute for Research and medical consultations (IRMC)UnknownHospitalized Patients | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection) | Laboratory-confirmed SARS-CoV 2 InfectionSaudi Arabia
-
Stanford UniversityPfizerCompletedLong COVID | Post-acute Sequelae of SARS-CoV-2 InfectionUnited States
Clinical Trials on Nasal Photodisinfection
-
Sunnybrook Health Sciences CentreCompletedCOVID-19 | SARS-CoV 2 | Corona Virus InfectionCanada
-
Zekai Tahir Burak Women's Health Research and Education...UnknownTransient Tachypnea of NewbornTurkey
-
Imperial College LondonNovartis PharmaceuticalsCompleted
-
University Hospital OstravaUniversity of OstravaRecruitingNasal Obstruction | Pituitary Adenoma InvasiveCzechia
-
GlaxoSmithKlineCompletedSleep Disorders | Congestion, NasalUnited States
-
Aardvark Medical CompanyCompletedSinusitis | Allergic Rhinitis | Nasal Congestion | Respiratory Tract InfectionUnited States
-
Universitaire Ziekenhuizen KU LeuvenUnknown
-
Radboud University Medical CenterCompleted
-
Indonesia UniversityNot yet recruitingNasal Mask | Nasal Prong